CLINICAL TRIALS PROFILE FOR SETANAXIB
✉ Email this page to a colleague
Clinical Trials for Setanaxib
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT04327089 ↗ | Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects | Completed | Genkyotex SA | Phase 1 | The study is a monocentric, open label, phase 1 study to evaluate the pharmacokinetics, and in particular the dose proportionality of setanaxib and its metabolites after a single oral dose (400 mg, 800 mg, 1200 mg, and 1600 mg) (Part 1) and after multiple oral doses (Part 2). |
NCT05014672 ↗ | A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness | Not yet recruiting | Genkyotex Suisse SA | Phase 2/Phase 3 | The primary objective of this study is to evaluate the effect of setanaxib on biochemical response at Week 52 in participants with primary biliary cholangitis (PBC) and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA). |
NCT05323656 ↗ | A Phase 2, Randomised Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic SCCHN | Recruiting | Genkyotex Suisse SA | Phase 2 | The primary objective of this study is to compare the change in tumour size per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in recurrent or metastatic SCCHN patients treated with setanaxib and pembrolizumab versus patients treated with placebo and pembrolizumab. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Setanaxib
Condition Name
Clinical Trial Locations for Setanaxib
Trials by Country
Clinical Trial Progress for Setanaxib
Clinical Trial Phase
Clinical Trial Sponsors for Setanaxib
Sponsor Name